Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Abstract 4599: Somatic mutation profile differences of “driver” mutations in 26 oncogenic lung cancer genes between African American and European American non-small cell lung cancer patients

Sarah H. Stephens, Patrice J. Fleming, Braxton D. Mitchell, Nicholas Ambulos, Joan E. Bailey-Wilson, Christy Chang, Josephine L. Feliciano, Edward A. Sausville, Martin J. Edelman

Cancer Res (2015) 75 (15_Supplement): 4599.

https://doi.org/10.1158/1538-7445.AM2015-4599

Published: 01 August 2015

View article titled, Abstract 4599: Somatic mutation profile differences of “driver” mutations in 26 oncogenic lung cancer genes between African American and European American non-small cell lung cancer patients

Journal Articles

Abstract 3268: Targeting leukemia metabolism: augmentation of anti-leukemic activity of arsenic trioxide (As₂O₃) against non-APL AML cell lines in presence of dichloroacetate (DCA).

Ashkan Emadi, Mariola Sadowska, Brandon A. Carter-Cooper, Rena G. Lapidus, Edward A. Sausville

Cancer Res (2013) 73 (8_Supplement): 3268.

https://doi.org/10.1158/1538-7445.AM2013-3268

Published: 15 April 2013

View article titled, Abstract 3268: Targeting leukemia metabolism: augmentation of anti-leukemic activity of arsenic trioxide (As2O3) against non-APL AML cell lines in presence of dichloroacetate (DCA).

Journal Articles

Abstract 5413: Maximal Power Design and Analysis of Drug Combination Studies: Applications to Vorinostat with Cytosine Arabinoside and Etoposide and Other Combination Studies

Hong-Bin Fang, Douglas D. Ross, Martin J. Edelman, Edward A. Sausville, Wei Li, Ming T. Tan

Cancer Res (2010) 70 (8_Supplement): 5413.

https://doi.org/10.1158/1538-7445.AM10-5413

Published: 15 April 2010

View article titled, Abstract 5413: Maximal Power Design and Analysis of Drug Combination Studies: Applications to Vorinostat with Cytosine Arabinoside and Etoposide and Other Combination Studies

Journal Articles

Response of breast cancer cell lines to aminoflavone (NSC 686288) is associated with histone H2AX phosphorylation and estrogen receptor expression

Melinda K. Wilson, Erica Stone, Michele Vitolo, Kurt Bachman, Brian Leyland-Jones, Angelika M. Burger, Edward A. Sausville

Cancer Res (2006) 66 (8_Supplement): 132.

Published: 15 April 2006

View article titled, Response of breast cancer cell lines to aminoflavone (NSC 686288) is associated with histone H2AX phosphorylation and estrogen receptor expression

Journal Articles

Response of melanoma cells to 17-allylamino-geldanamycin is associated with modulation of extracellular Hsp90 and MMP2

Sivalakshmi Veerasamy, Kate Malone, Edward A. Sausville, Angelika M. Burger

Cancer Res (2006) 66 (8_Supplement): 273.

Published: 15 April 2006

View article titled, Response of melanoma cells to 17-allylamino-geldanamycin is associated with modulation of extracellular Hsp90 and MMP2

Journal Articles

Contributions of Human Tumor Xenografts to Anticancer Drug Development

Edward A. Sausville, Angelika M. Burger

Cancer Res (2006) 66 (7): 3351–3354.

https://doi.org/10.1158/0008-5472.CAN-05-3627

Published: 03 April 2006

View article titled, Contributions of Human Tumor Xenografts to Anticancer Drug Development

Journal Articles

Ligand-Directed Surface Profiling of Human Cancer Cells with Combinatorial Peptide Libraries

Mikhail G. Kolonin, Laura Bover, Jessica Sun, Amado J. Zurita, Kim-Anh Do, Johanna Lahdenranta, Marina Cardó-Vila, Ricardo J. Giordano, Diana E. Jaalouk, Michael G. Ozawa, Catherine A. Moya, Glauco R. Souza, Fernanda I. Staquicini, Akihiko Kunyiasu, Dominic A. Scudiero, Susan L. Holbeck, Edward A. Sausville, Wadih Arap, Renata Pasqualini

Cancer Res (2006) 66 (1): 34–40.

https://doi.org/10.1158/0008-5472.CAN-05-2748

Published: 05 January 2006

View article titled, Ligand-Directed Surface Profiling of Human Cancer Cells with Combinatorial Peptide Libraries

Includes: Supplementary data

Journal Articles

Mammalian Target of Rapamycin, a Molecular Target in Squamous Cell Carcinomas of the Head and Neck

Panomwat Amornphimoltham, Vyomesh Patel, Akrit Sodhi, Nikolaos G. Nikitakis, John J. Sauk, Edward A. Sausville, Alfredo A. Molinolo, J. Silvio Gutkind

Cancer Res (2005) 65 (21): 9953–9961.

https://doi.org/10.1158/0008-5472.CAN-05-0921

Published: 01 November 2005

View article titled, Mammalian Target of Rapamycin, a Molecular Target in Squamous Cell Carcinomas of the Head and Neck

Journal Articles

Benzodithiophenes Induce Differentiation and Apoptosis in Human Leukemia Cells

Yongkui Jing, Nella Hellinger, Lijuan Xia, Anne Monks, Edward A. Sausville, Arthur Zelent, Samuel Waxman

Cancer Res (2005) 65 (17): 7847–7855.

https://doi.org/10.1158/0008-5472.CAN-05-1053

Published: 01 September 2005

View article titled, Benzodithiophenes Induce Differentiation and Apoptosis in Human Leukemia Cells

Journal Articles

Factors affecting the pharmacokinetic profile of MS-275, a histone deacetylase inhibitor, in humans

Milin R. Acharya, Judith E. Karp, Edward A. Sausville, Kyunghwa Hwang, Qin Ryan, Ivana Gojo, Jurgen Venitz, William D. Figg, Alex Sparreboom

Cancer Res (2005) 65 (9_Supplement): 937.

Published: 01 May 2005

View article titled, Factors affecting the pharmacokinetic profile of MS-275, a histone deacetylase inhibitor, in humans

Journal Articles

Expression of Hsp90 in a panel of human tumor explants and its relation to response to treatment with the Hsp90 inhibitor 17-AAG.

Kathrin Schandelmaier, Heinz-Herbert Fiebig, Edward A. Sausville, Angelika M. Burger

Cancer Res (2005) 65 (9_Supplement): 104.

Published: 01 May 2005

View article titled, Expression of Hsp90 in a panel of human tumor explants and its relation to response to treatment with the Hsp90 inhibitor 17-AAG.

Journal Articles

Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor

Milin R. Acharya, Alex Sparreboom, Edward A. Sausville, Barbara A. Conley, James H. Doroshow, Jurgen Venitz, William D. Figg

Cancer Res (2005) 65 (9_Supplement): 983.

Published: 01 May 2005

View article titled, Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor

Journal Articles

In vivo Models for Experimental Therapeutics Relevant to Human Cancer

Miriam S. Gitler, Edward A. Sausville, Melinda Hollingshead, Robert Shoemaker

Cancer Res (2004) 64 (22): 8478–8480.

https://doi.org/10.1158/0008-5472.CAN-04-2057

Published: 17 November 2004

View article titled, In vivo Models for Experimental Therapeutics Relevant to Human Cancer

Journal Articles

SJG-136 (NSC 694501), A Novel Rationally Designed DNA Minor Groove Interstrand Cross-Linking Agent with Potent and Broad Spectrum Antitumor Activity: Part 2: Efficacy Evaluations

Michael C. Alley, Melinda G. Hollingshead, Christine M. Pacula-Cox, William R. Waud, John A. Hartley, Philip W. Howard, Stephen J. Gregson, David E. Thurston, Edward A. Sausville

Cancer Res (2004) 64 (18): 6700–6706.

https://doi.org/10.1158/0008-5472.CAN-03-2942

Published: 16 September 2004

View article titled, SJG-136 (NSC 694501), A Novel Rationally Designed DNA Minor Groove Interstrand Cross-Linking Agent with Potent and Broad Spectrum Antitumor Activity: <subtitle>Part 2: Efficacy Evaluations</subtitle>

Journal Articles

SJG-136 (NSC 694501), a Novel Rationally Designed DNA Minor Groove Interstrand Cross-Linking Agent with Potent and Broad Spectrum Antitumor Activity: Part 1: Cellular Pharmacology, In vitro and Initial In vivo Antitumor Activity

John A. Hartley, Victoria J. Spanswick, Natalie Brooks, Peter H. Clingen, Peter J. McHugh, Daniel Hochhauser, R. Barbara Pedley, Lloyd R. Kelland, Michael C. Alley, Robert Schultz, Melinda G. Hollingshead, Karen M. Schweikart, Joseph E. Tomaszewski, Edward A. Sausville, Stephen J. Gregson, Philip W. Howard, David E Thurston

Cancer Res (2004) 64 (18): 6693–6699.

https://doi.org/10.1158/0008-5472.CAN-03-2941

Published: 16 September 2004

View article titled, SJG-136 (NSC 694501), a Novel Rationally Designed DNA Minor Groove Interstrand Cross-Linking Agent with Potent and Broad Spectrum Antitumor Activity: <subtitle>Part 1: Cellular Pharmacology, In vitro and Initial In vivo Antitumor Activity</subtitle>

Journal Articles

Development of an in vitro model for alveolar soft part sarcoma (ASPS)

David T. Vistica, Susan Kenney, Jamie Boswell, David S. Schrump, Lee Helman, Martin Malawer, Robert Shoemaker, Edward A. Sausville

Cancer Res (2004) 64 (7_Supplement): 265.

Published: 01 April 2004

View article titled, Development of an in vitro model for alveolar soft part sarcoma (ASPS)

Journal Articles

A novel angiogenesis inhibitor: Adaphostin (NSC 680410)

Gurmeet Kaur, Kirsten Fisher-Nielsen, Jagada Thillainathan, Ven Narayanan, Prabhakar Risbood, Melinda Hollingshead, Edward A. Sausville

Cancer Res (2004) 64 (7_Supplement): 946.

Published: 01 April 2004

View article titled, A novel angiogenesis inhibitor: Adaphostin (NSC 680410)

Journal Articles

In vitro and in vivo evaluations of artemisinin derivatives with potent and unique anticancer activities.

Michael C. Alley, Melinda G. Hollingshead, Sherman F. Stinson, Susan Holbeck, Shannon Decker, Mahmoud A. Elsohly, Ahmed M. Galal, Samir A. Ross, Edward A. Sausville

Cancer Res (2004) 64 (7_Supplement): 577.

Published: 01 April 2004

View article titled, In vitro and in vivo evaluations of artemisinin derivatives with potent and unique anticancer activities.

Journal Articles

Release of intracellular free iron may be responsible for generation of reactive oxygen species and toxicity of adaphostin

Anne Monks, Curtis D. Hose, Gurmeet Kaur, Edward A. Sausville

Cancer Res (2004) 64 (7_Supplement): 349.

Published: 01 April 2004

View article titled, Release of intracellular free iron may be responsible for generation of reactive oxygen species and toxicity of adaphostin

Journal Articles

Novel geldanamycin target involved in the inhibition of theHGF/MET pathway

Qian Xie, Chong Feng Gao, Nariyoshi Shinomiya, Margaret Gustafson, Edward A. Sausville, David Wenkert, Yuehai Shen, George F. Vande Woude

Cancer Res (2004) 64 (7_Supplement): 1238.

Published: 01 April 2004

View article titled, Novel geldanamycin target involved in the inhibition of theHGF/MET pathway

NARROW

Abstract 4599: Somatic mutation profile differences of “driver” mutations in 26 oncogenic lung cancer genes between African American and European American non-small cell lung cancer patients

Abstract 3268: Targeting leukemia metabolism: augmentation of anti-leukemic activity of arsenic trioxide (As₂O₃) against non-APL AML cell lines in presence of dichloroacetate (DCA).

Abstract 5413: Maximal Power Design and Analysis of Drug Combination Studies: Applications to Vorinostat with Cytosine Arabinoside and Etoposide and Other Combination Studies

Response of breast cancer cell lines to aminoflavone (NSC 686288) is associated with histone H2AX phosphorylation and estrogen receptor expression

Response of melanoma cells to 17-allylamino-geldanamycin is associated with modulation of extracellular Hsp90 and MMP2

Contributions of Human Tumor Xenografts to Anticancer Drug Development

Ligand-Directed Surface Profiling of Human Cancer Cells with Combinatorial Peptide Libraries

Mammalian Target of Rapamycin, a Molecular Target in Squamous Cell Carcinomas of the Head and Neck

Benzodithiophenes Induce Differentiation and Apoptosis in Human Leukemia Cells

Factors affecting the pharmacokinetic profile of MS-275, a histone deacetylase inhibitor, in humans

Expression of Hsp90 in a panel of human tumor explants and its relation to response to treatment with the Hsp90 inhibitor 17-AAG.

Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor

In vivo Models for Experimental Therapeutics Relevant to Human Cancer

SJG-136 (NSC 694501), A Novel Rationally Designed DNA Minor Groove Interstrand Cross-Linking Agent with Potent and Broad Spectrum Antitumor Activity: Part 2: Efficacy Evaluations

SJG-136 (NSC 694501), a Novel Rationally Designed DNA Minor Groove Interstrand Cross-Linking Agent with Potent and Broad Spectrum Antitumor Activity: Part 1: Cellular Pharmacology, In vitro and Initial In vivo Antitumor Activity

Development of an in vitro model for alveolar soft part sarcoma (ASPS)

A novel angiogenesis inhibitor: Adaphostin (NSC 680410)

In vitro and in vivo evaluations of artemisinin derivatives with potent and unique anticancer activities.

Release of intracellular free iron may be responsible for generation of reactive oxygen species and toxicity of adaphostin

Novel geldanamycin target involved in the inhibition of theHGF/MET pathway

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only